Phospholipid-mediated signaling in diseased myocardium-Reference-Cited by-同舟云学术

Phospholipid-mediated signaling in diseased myocardium

Published:2006-12-01 Issue:6 Volume:1 Page:701-717
ISSN:1746-0875
Container-title:Future Lipidology
language:en
Short-container-title:Future Lipidology

Author:

Tappia Paramjit¹,Singal Tushi²,Dent Melissa²,Asemu Girma³,Rabban Mangat⁴,Naranjan Dhalla⁵

Affiliation:

1. Institute of Cardiovascular Sciences, Laboratory of Cardiac Membrane Biology, St Boniface General Hospital Research Centre (R3020), 351 Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada, Tel.: ; Fax.: ,

2. Laboratory of Cardiac Membrane Biology,Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center & Department of Physiology, University of Manitoba, Canada, Tel.: ; Fax.: ,

3. Laboratory of Clinical Investigation,, Baltimore, Maryland, USA, Tel.: ;

4. Department of Agricultural, Food & Nutritional Sciences, University of Alberta, Edmonton, Canada, Tel.: ; Fax.: ,

5. Laboratory of Experimental Cardiology, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center & Department of Physiology, University of Manitoba, Canada, Tel.: ; Fax.: ,

Publisher

Informa UK Limited

Subject

Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.2217/17460875.1.6.701

Reference177 articles.

1. 1. Lamers JMJ, Dekkers DH, Bezstarosti K, Meij JT, van Heugten HA: Occurrence and functions of the phosphatidylinositol cycle in the myocardium. Mol. Cell Biochem. 116, 59–67 (1992).

2. Dhalla NS, Dent MR, Tappia PS, Sethi R, Bartha J, Goyal RK: Subcellular remodeling as a viable target for the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. Ther. 11, 31–45 (2006).

3. Tappia PS, Dent MR, Dhalla NS: Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med. 41, 349–361 (2006).

4. Tappia PS, Liu SY, Shatadal S, Takeda N, Dhalla NS, Panagia V: Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am. J. Physiol. Heart Circ. Physiol. 277(1 Pt 2), H40–H49 (1999).

5. Park JB, Kim JH, Kim Y et al.: Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by -actinin in an ADP-ribosylation factor-reversible manner. J. Biol. Chem. 275(28), 21295–21301 (2000).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phospholipase activities in cardiovascular disease and its role as a potential biomarker in heart failure;Phospholipases in Physiology and Pathology;2023

2. Association of phospholipase C and D in cardiovascular risk prediction and progression;Phospholipases in Physiology and Pathology;2023

3. Case report of primary membranous nephropathy associated with muscle and peripheral nerve damage;Nephrology (Saint-Petersburg);2022-09-11

4. Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors;Scripta Medica;2022

5. Role of angiotensin II in the development of subcellular remodeling in heart failure;Exploration of Medicine;2021-08-31